Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Benefits"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
dewey-ones:"330 - Economics"
language:"English"
Showing
21
-
40
of
231
Search:
'"Benefits"'
,
query time: 0.02s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
21
Antibiotic impregnated cement for primary hip or knee arthroplasty : a review of the clinical and cost-effectiveness
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
22
Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses : an economic analysis and budget impact analysis
by
Membe, Stephen K.
Published 2011
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
23
Debridement procedures for managing diabetic foot ulcers : a review of clinical effectiveness, cost-effectiveness, and guidelines
Published 2014
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
24
Pharmacoeconomic review report: Guselkumab (Tremfya) (Janssen Inc.)
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
25
Pharmacoeconomic review report: Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.)
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
26
Pharmacoeconomic review report: Lanadelumab (Takhzyro) (Shire pharma Canada ULC) : indication : for the routine prevention of attacks of hereditary angioedema in adolescents and ad...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
27
Clinical review report: Inotersen (Tegsedi) (Akcea therapeutics, inc.) : indication: stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATT...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
28
CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
29
Clinical decision support systems for appropriate medical imaging : clinical evidence and cost-effectiveness
by
Edge, Rob
,
Ford, Caitlyn
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
30
Pharmacoeconomic review report: Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.)
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
31
Switching from innovator to biosimilar (subsequent entry) infliximab : an updated review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
32
Direct oral anticoagulants for the treatment of venous thromboembolic events : economic evaluation
by
Klarenbach, Scott
Published 2016
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
33
Ulipristal versus levonorgestrel for emergency contraception : a review of comparative cost-effectiveness
by
Tran, Khai
,
Grobelna, Aleksandra
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
34
Pharmacoeconomic review report: Inotersen (Tegsedi) (Akcea Therapeutics, Inc.) : indication : stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloido...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
35
Pharmacoeconomic review report: Cyclosporine (Verkazia) (Santen Canada inc.) : indication: treatment of severe vernal keratoconjunctivitis in children from four years of age throug...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
36
Pharmacoeconomic review report: Upadacitinib (Rinvoq) (AbbVie) : indication: for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an ina...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
37
Deep brain stimulation for Parkinson's disease : a review of clinical effectiveness, cost-effectiveness, and guidelines
by
Lachance, Chantelle
,
Spry, Carolyn
,
MacDougall, Danielle
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
38
Ulipristal versus levonorgestrel for emergency contraception : a review of comparative cost-effectiveness
by
Tran, Khai
,
Grobelna, Aleksandra
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
39
Pharmacoeconomic review report: Mifepristone and misoprostol (Mifegymiso)
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
40
Pharmacoeconomic review report: Apomorphine (Movapo) (Paladin Labs, Inc.)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
1
2
3
4
5
6
7
8
9
10
11
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Classification: 330 - Economics
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
330 - Economics
610 - Medicine & health
76
140 - Specific philosophical schools
19
700 - The arts; fine & decorative arts
17
580 - Plants (Botany)
3
600 - Technology
2
more ...
615 - Pharmacology & therapeutics
2
100 - Philosophy & psychology
1
363 - Other social problems & services
1
800 - Literature & rhetoric
1
see all ...
less ...
Language
English
Collection
National Center for Biotechnology Information
231
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
50
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
27
Adcock, Lorna
7
Ho, Chuong
7
Ford, Caitlyn
6
more ...
Grobelna, Aleksandra
5
Argáez, Charlene
4
Chao, Yi-Sheng
4
Gray, Casey
4
McCormack, Suzanne
4
Tran, Khai
4
Banerjee, Srabani
3
Campbell, Kaitryn
3
Loshak, Hannah
3
MacDougall, Danielle
3
Wells, Charlotte
3
Williams, D.
3
Young, Calvin
3
Farrah, Kelly
2
Frey, Nina
2
Jahagirdar, Deepa
2
Kanga, Ismat
2
Poitras, Veronica
2
Visintini, Sarah
2
Adams, Alison
1
Chiu, Stephanie
1
Cowling, Tara
1
De Nanassy, Alina
1
Edge, Rob
1
Harricharan, Sharada
1
Khangura, Sara
1
Klarenbach, Scott
1
Krahn, Murray
1
La Fleur, Philip
1
Lachance, Chantelle
1
Lee, Karen M.
1
Marchand, Dave K.
1
Membe, Stephen K.
1
Narain, Tasha
1
Palylyk-Colwell, Eugenia
1
Picheca, Lory
1
Singh, Sumeet
1
Spry, Carolyn
1
Thompson, Wade
1
Wong, William
1
Wright, Mary-Doug
1
Yeung, Shirley S. T.
1
see all ...
less ...
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?page=2&filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=dewey-ones%3A%22330+-+Economics%22&filter%5B%5D=language%3A%22English%22&lookfor=%22Benefits%22&type=Subject
Send by Email
×
Loading...